Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
Jefferies analyst Anthony Petrone maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $105.
Jefferies analyst Anthony Petrone maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $105.